KR102529353B1 - 인슐린 유사체 - Google Patents

인슐린 유사체 Download PDF

Info

Publication number
KR102529353B1
KR102529353B1 KR1020197004760A KR20197004760A KR102529353B1 KR 102529353 B1 KR102529353 B1 KR 102529353B1 KR 1020197004760 A KR1020197004760 A KR 1020197004760A KR 20197004760 A KR20197004760 A KR 20197004760A KR 102529353 B1 KR102529353 B1 KR 102529353B1
Authority
KR
South Korea
Prior art keywords
delete delete
insulin
chain
cys
peptide
Prior art date
Application number
KR1020197004760A
Other languages
English (en)
Korean (ko)
Other versions
KR20190039719A (ko
Inventor
존 거브란트 태즈먼 멘팅
브라이언 스미스
데니 훙-치에 처우
헬레나 사파비-헤마미
마이클 콜린 로렌스
올리베라 엠 발도메로
Original Assignee
유타대학연구재단
더 월터 앤드 엘리자 홀 인스티튜트 오브 메디컬 리서치
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2016902883A external-priority patent/AU2016902883A0/en
Application filed by 유타대학연구재단, 더 월터 앤드 엘리자 홀 인스티튜트 오브 메디컬 리서치 filed Critical 유타대학연구재단
Priority to KR1020237015079A priority Critical patent/KR20230070049A/ko
Priority claimed from PCT/AU2017/050758 external-priority patent/WO2018014091A1/fr
Publication of KR20190039719A publication Critical patent/KR20190039719A/ko
Application granted granted Critical
Publication of KR102529353B1 publication Critical patent/KR102529353B1/ko

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43509—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from crustaceans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • C—CHEMISTRY; METALLURGY
    • C30—CRYSTAL GROWTH
    • C30B—SINGLE-CRYSTAL GROWTH; UNIDIRECTIONAL SOLIDIFICATION OF EUTECTIC MATERIAL OR UNIDIRECTIONAL DEMIXING OF EUTECTOID MATERIAL; REFINING BY ZONE-MELTING OF MATERIAL; PRODUCTION OF A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; SINGLE CRYSTALS OR HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; AFTER-TREATMENT OF SINGLE CRYSTALS OR A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; APPARATUS THEREFOR
    • C30B29/00—Single crystals or homogeneous polycrystalline material with defined structure characterised by the material or by their shape
    • C30B29/54—Organic compounds
    • C30B29/58—Macromolecular compounds
    • C—CHEMISTRY; METALLURGY
    • C30—CRYSTAL GROWTH
    • C30B—SINGLE-CRYSTAL GROWTH; UNIDIRECTIONAL SOLIDIFICATION OF EUTECTIC MATERIAL OR UNIDIRECTIONAL DEMIXING OF EUTECTOID MATERIAL; REFINING BY ZONE-MELTING OF MATERIAL; PRODUCTION OF A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; SINGLE CRYSTALS OR HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; AFTER-TREATMENT OF SINGLE CRYSTALS OR A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; APPARATUS THEREFOR
    • C30B7/00—Single-crystal growth from solutions using solvents which are liquid at normal temperature, e.g. aqueous solutions
    • C30B7/02—Single-crystal growth from solutions using solvents which are liquid at normal temperature, e.g. aqueous solutions by evaporation of the solvent
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
    • G16B15/30—Drug targeting using structural data; Docking or binding prediction
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H15/00—ICT specially adapted for medical reports, e.g. generation or transmission thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Materials Engineering (AREA)
  • Metallurgy (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Theoretical Computer Science (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Evolutionary Biology (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
KR1020197004760A 2016-07-22 2017-07-21 인슐린 유사체 KR102529353B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020237015079A KR20230070049A (ko) 2016-07-22 2017-07-21 인슐린 유사체

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
AU2016902883A AU2016902883A0 (en) 2016-07-22 Insulin Analogs
AU2016902883 2016-07-22
US201762483118P 2017-04-07 2017-04-07
US62/483,118 2017-04-07
PCT/AU2017/050758 WO2018014091A1 (fr) 2016-07-22 2017-07-21 Analogues de l'insuline

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020237015079A Division KR20230070049A (ko) 2016-07-22 2017-07-21 인슐린 유사체

Publications (2)

Publication Number Publication Date
KR20190039719A KR20190039719A (ko) 2019-04-15
KR102529353B1 true KR102529353B1 (ko) 2023-05-04

Family

ID=65524551

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020197004760A KR102529353B1 (ko) 2016-07-22 2017-07-21 인슐린 유사체
KR1020237015079A KR20230070049A (ko) 2016-07-22 2017-07-21 인슐린 유사체

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020237015079A KR20230070049A (ko) 2016-07-22 2017-07-21 인슐린 유사체

Country Status (15)

Country Link
US (2) US11248034B2 (fr)
EP (1) EP3487876A4 (fr)
JP (2) JP7143275B2 (fr)
KR (2) KR102529353B1 (fr)
CN (2) CN116874584A (fr)
AU (1) AU2021269301B2 (fr)
BR (1) BR112019000991A2 (fr)
CL (1) CL2019000159A1 (fr)
CR (1) CR20190096A (fr)
IL (1) IL264330B2 (fr)
MA (1) MA45727A (fr)
MX (1) MX2019000829A (fr)
RU (1) RU2769476C2 (fr)
SG (1) SG11201900181RA (fr)
ZA (1) ZA201901095B (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018045018A1 (fr) * 2016-08-30 2018-03-08 Board Of Regents, The University Of Texas System Production de séléno-biologiques dans des organismes génétiquement recodés
WO2023229624A1 (fr) * 2022-05-26 2023-11-30 Transdermal Delivery Solutions Corp. (D.B.A. Hypospray Pharma) Formulations transdermiques d'insuline et leurs procédés d'utilisation

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012174480A2 (fr) 2011-06-17 2012-12-20 Halozyme, Inc. Procédés de perfusion d'insuline sous-cutanée continue utilisant une enzyme de dégradation de l'hyaluronane
JP2014129355A (ja) 2006-09-22 2014-07-10 Novo Nordisk As プロテアーゼ耐性のインスリンアナログ

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2104305C1 (ru) * 1986-08-29 1998-02-10 Ново Нордиск А.С. Аналоги инсулина человека, способ их получения, раствор для инъекций
WO2005095443A1 (fr) * 2004-03-31 2005-10-13 Cardio Incorporated Système d'administration médicamenteuse utilisant un peptide modifié
US7790677B2 (en) * 2006-12-13 2010-09-07 Elona Biotechnologies Insulin production methods and pro-insulin constructs
WO2010014946A2 (fr) * 2008-07-31 2010-02-04 Case Western Reserve University Insuline stabilisée par de l'halogène
US9200053B2 (en) * 2008-07-31 2015-12-01 Case Western Reserve University Insulin analogues containing penta-fluoro-Phenylalanine at position B24
WO2010066636A1 (fr) * 2008-12-09 2010-06-17 Novo Nordisk A/S Nouveaux analogues de l'insuline
US8399407B2 (en) * 2009-09-17 2013-03-19 Case Western Reserve University Non-standard insulin analogues
RU2678134C2 (ru) * 2013-03-14 2019-01-23 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Конъюгаты инсулин-инкретин
US20160083448A1 (en) 2013-03-15 2016-03-24 Case Western Reserve University Site 2 insulin analogues
JP2016523241A (ja) * 2013-06-14 2016-08-08 プレジデント アンド フェローズ オブ ハーバード カレッジ 安定化されたポリペプチドインスリン受容体調節剤
AU2017298565B2 (en) 2016-07-22 2021-08-19 The Walter And Eliza Hall Institute Of Medical Research Insulin analogs

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014129355A (ja) 2006-09-22 2014-07-10 Novo Nordisk As プロテアーゼ耐性のインスリンアナログ
WO2012174480A2 (fr) 2011-06-17 2012-12-20 Halozyme, Inc. Procédés de perfusion d'insuline sous-cutanée continue utilisant une enzyme de dégradation de l'hyaluronane

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PNAS, 112(6), 1743-1748, 2015.*

Also Published As

Publication number Publication date
IL264330B2 (en) 2024-05-01
SG11201900181RA (en) 2019-02-27
JP2019534843A (ja) 2019-12-05
EP3487876A4 (fr) 2020-02-19
IL264330B1 (en) 2024-01-01
CR20190096A (es) 2019-09-16
RU2769476C2 (ru) 2022-04-01
CN110072884A (zh) 2019-07-30
KR20230070049A (ko) 2023-05-19
JP7143275B2 (ja) 2022-09-28
EP3487876A1 (fr) 2019-05-29
KR20190039719A (ko) 2019-04-15
MX2019000829A (es) 2019-08-29
JP2022191233A (ja) 2022-12-27
CN110072884B (zh) 2023-07-28
CN116874584A (zh) 2023-10-13
NZ750355A (en) 2023-10-27
RU2019100497A3 (fr) 2021-05-11
IL264330A (fr) 2019-03-31
US11248034B2 (en) 2022-02-15
US20190241640A1 (en) 2019-08-08
AU2021269301A1 (en) 2021-12-09
CL2019000159A1 (es) 2019-08-16
US20220340636A1 (en) 2022-10-27
BR112019000991A2 (pt) 2019-07-02
MA45727A (fr) 2019-05-29
ZA201901095B (en) 2022-04-28
RU2019100497A (ru) 2020-08-24
AU2021269301B2 (en) 2023-12-21

Similar Documents

Publication Publication Date Title
AU2017298565B2 (en) Insulin analogs
EP2411038B1 (fr) Peptides de l'hormone parathyroïdienne et peptides de la protéine apparentée à l'hormone parathyroïdienne ainsi que des procédés d'utilisation
Pioszak et al. Molecular recognition of corticotropin-releasing factor by its G-protein-coupled receptor CRFR1
Muttenthaler et al. Solving the α-conotoxin folding problem: efficient selenium-directed on-resin generation of more potent and stable nicotinic acetylcholine receptor antagonists
Luo et al. Atypical α-conotoxin LtIA from Conus litteratus targets a novel microsite of the α3β2 nicotinic receptor
EP2901154B1 (fr) Structure d'insuline dans un complexe avec des régions terminales en n et en c de la chaîne alpha du récepteur de l'insuline
JP2022191233A (ja) インスリンアナログ
US20090117662A1 (en) Mutants of IGF Binding Proteins and Methods of Production of Antagonists Thereof
Dong et al. Lactam constraints provide insights into the receptor-bound conformation of secretin and stabilize a receptor antagonist
Hopping et al. Hydrophobic residues at position 10 of α-conotoxin PnIA influence subtype selectivity between α7 and α3β2 neuronal nicotinic acetylcholine receptors
Thielmann et al. Structural framework of the GABARAP–calreticulin interface–implications for substrate binding to endoplasmic reticulum chaperones
US20030138848A1 (en) 3D structure of polypeptides containing a TPR-structure motif with chaperone-binding function, crystals thereof and compounds for inhibition of said polypeptides
Seow et al. Structure and characterisation of a key epitope in the conserved C-terminal domain of the malaria vaccine candidate MSP2
Asami et al. Physicochemically and pharmacokinetically stable nonapeptide KISS1 receptor agonists with highly potent testosterone-suppressive activity
NZ750355B2 (en) Insulin analogs
Žáková et al. Toward the Insulin− IGF-I Intermediate Structures: Functional and Structural Properties of the [TyrB25NMePheB26] Insulin Mutant
Henández et al. Disorder-to-Order Markers of a Cyclic Hexapeptide Inspired from the Binding Site of Fertilin β Involved in Fertilization Process
US20050260730A1 (en) CDK2/cyclin A crystals and uses thereof
WO2024042220A1 (fr) Modulateurs de l'activité de papp-a
Cheloha Exploration of α/β-peptides as parathyroid hormone receptor ligands and recognition of α/β-peptides by the immune system
Alcaro et al. Optimization of Multiple Sclerosis Antigenic Probes by a Combinatorial Approach
Watson Insulin analogues for insulin receptor studies and medical applications
Pandyarajan Structure-Function Relationships at a Hormone-Receptor Interface: Insulin Residues B24 and B26

Legal Events

Date Code Title Description
E902 Notification of reason for refusal
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant